151 / 172
151
64. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S,
Lems WF, Aarden L, et al. Anti-infliximab and anti-
adalimumab antibodies in relation to response to adalimumab
in infliximab switchers and anti-tumour necrosis factor naive
patients: a cohort study. Ann Rheum Dis 2010;69:817-21.
65. American College of Rheumatology Subcommittee on
rheumatoid arthritis guidelines. Guidelines for the
management of rheumatoid arthritis. Arthritis Rheum
2002;46:328-46.
66. Smolen
JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C,et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and
biological disease-modifying antirheumatic drugs.
Ann Rheum Dis 2010;69:964-75.
67. Dernis E, Ruyssen-Witrand A, Mouterde G, Maillefert JF,
Tebib J, Cantagrel A, et al. Use of glucocorticoids in
rheumatoid arthritis - pratical modalities of glucocorticoid
therapy: recommendations for clinical practice based on data
from the literature and expert opinion. Joint Bone Spine
2010;77:451-7.
68. Cronstein B. How does methotrexate suppress
inflammation? Clin Exp Rheumatol 2010;28(5 Suppl 61):S21-3.
69. Pincus T, Cronstein B, Braun J. Methotrexate--the anchor
drug—an introduction. Clin Exp Rheumatol 2010;28(5 Suppl
61):S1-2.
70. Pereira IA, Cruz BA, Xavier RM, Pinheiro GR, Titton D,
Giorgi R et al. National recommendations based on scientific
evidence and opinions of experts on the use of methotrexate in
rheumatic disorders, especially in rheumatoid arthritis: results
of the 3E Initiative from Brazil. Rev Bras Reumatol 2009;49:346-
61.
71
.Rozman B.Clinical pharmacokinetics of leflunomide.
Clin Pharmacokinet2002;41:421-30.